Business
Pharming Group to participate in August investor conference
Leiden, the Netherlands, August 4, 2025: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming’s management will participate in the following investor conference in the month of August: Canaccord Genuity 45th Annual Growth Conference, Boston, USA, August 12-13, 2025Fabrice Chouraqui, Chief Executive Officer, will present on Tuesday, August 12 at 12:00pm EDT/18:00 CEST. For more information about this conference, or to schedule a one-to-one meeting with
About this update from Pharming Group Nv
Leiden, the Netherlands, August 4, 2025: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming’s management will participate in the following investor conference in the month of August: For more information about this conference, or to schedule a one-to-one meeting with Pharming’s management team, please contact Pharming’s Investor Relations team at [email protected] or your Canaccord Genuity representative. About Pharming Group N.V. Pharming Group N.V. (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. We are commercializing and developing a portfolio of innovative medicines, including small molecules and biologics. Pharming is headquartered in Leiden, the Netherlands, and has employees around the globe who serve patients in over 30 markets in North America, Europe, the Middle East, Africa, and Asia-Pacific. For more information, visit www.pharming.com and find us on LinkedIn . For further public information, contact: Pharming Group, Leiden, the Netherlands Michael Levitan, VP Investor Relations & Corporate Communications T: +1 (908) 705 1696 E: [email protected] FTI Consulting, London, United Kingdom Simon Conway/Alex Shaw/Amy Byrne T: +44 203 727 1000 LifeSpring Life Sciences Communication, Amsterdam, the Netherlands Leon Melens T: +31 6 53 81 64 27 E: [email protected] Attachment